PremiumRatingsPalvella Therapeutics: Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating High-Impact Catalyst: Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Gel and Favorable Regulatory Environment Palvella Therapeutics price target raised to $70 from $30 at Cantor Fitzgerald PremiumThe FlyTesla upgraded, Coinbase initiated: Wall Street’s top analyst calls Positive Outlook on Palvella Therapeutics: Buy Rating Backed by Promising QTORIN Rapamycin Potential Palvella Therapeutics initiated with an Outperform at Scotiabank PremiumThe FlyPalvella Therapeutics initiated with a Buy at Canaccord Palvella Therapeutics to expand Phase 3 SELVA trial to include younger patients Palvella Therapeutics initiated with a Buy at TD Cowen 
